| Chair: Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain |
|
| 08:30 - 08:50 | Immunotherapy maintenance Dr. Kristoffer Hellstrand, University of Gothenburg, Göteborg, Sweden |
| Chair: Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain |
|
| 08:50 - 09:10 | Oral Azacitidine maintenance Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
| Chair: Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy |
|
| 09:10 - 09:30 | FLT-3 inhibitors maintenance Dr. Andrius Žučenka, Vilnius University Hospital Santaros Klinikos, Vilna, Lithuania |
| 09:30 - 09:45 | Discussion |
| Chairs: Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy |
|
| 09:45 - 10:05 | Characterisation and diagnosis Dr. Claudio Cerchione, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy |
| 10:05 - 10:25 | Treatment of BPDCN Dr. Josefina Serrano, Hospital Univ. Reina Sofía, Córdoba, Spain |
| 10:25 - 10:45 | Real-life experience and practical aspects Dr. Pedro Paúl, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain |
| 10:45 - 11:00 | Conclusions |
| Chairs: Dr. Adrián Mosquera, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
|
| 11:30 - 11:50 | Computer vision for automatic diagnosis of AML from bone marrow smears Dr. Jan-Niklas Eckardt, University Hospital Carl Gustav Carus, Dresden, Germany |
| 11:50 - 12:10 | Subclassification of primary and secondary AML based on genomic profiles using AI Dr. Torsten Haferlach, Munich Leukemia Laboratory, Munich, Germany |
| 12:10 - 12:30 | Risk prediction in myelofibrosis and MDS with machine-learning tools Dr. Adrián Mosquera, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain |
| 12:30 - 12:45 | Discussion |
| Chairs: Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy Dr. Claudio Cerchione, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” - IRST, Meldola, Italy |
|
| 12:45 - 13:05 | Management of high-risk AML Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain |
| 13:05 - 13:25 | Vyxeos in young patients with Secondary AML Dr. Priyanka Mehta, University Hospitals Bristol and Weston, Bristol, UK |
| 13:25 - 13:40 | Discussion |
| Chairs: Dr. David Valcárcel,Institute of Oncology, Hospital Quirónsalud Barcelona, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |
|
| 13:40 - 14:00 | New approaches for anemai in MDS Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA |
| 14:00 - 14:20 | High risk MDS Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain |
| 14:20 - 14:35 | Discussion |
| Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain |